{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:56:45Z","timestamp":1793120205858,"version":"4.5.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"am","delay-in-days":392,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.therap.2023.09.007","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T22:58:23Z","timestamp":1698793103000},"page":"173-179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Drug-induced psychiatric disorders: A pharmacovigilance update"],"prefix":"10.1016","volume":"79","author":[{"given":"Fran\u00e7ois","family":"Montastruc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanguy","family":"Taillefer de Laportaliere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2023.09.007_bib0300","series-title":"Diagnostic and statistical manual of mental disorders","year":"2013"},{"key":"10.1016\/j.therap.2023.09.007_bib0305","unstructured":"Le Manuel MSD. Comportement suicidaire. 2021. https:\/\/www.msdmanuals.com\/fr\/professional\/troubles-psychiatriques\/comportement-suicidaire-et-automutilation\/comportement-suicidaire [Accessed 29 August 2023]"},{"key":"10.1016\/j.therap.2023.09.007_bib0310","series-title":"Petit manuel des troubles d\u2019origines m\u00e9dicamenteuse","author":"Prescrire","year":"2021"},{"key":"10.1016\/j.therap.2023.09.007_bib0315","series-title":"EMC Psychiatrie","article-title":"Effets secondaires psychiatriques des m\u00e9dicaments non psychotropes","author":"Gourevitch","year":"2005"},{"key":"10.1016\/j.therap.2023.09.007_bib0320","series-title":"Psychiatrie de liaison","first-page":"531","article-title":"Effets secondaires psychiatriques des m\u00e9dicaments \u00e0 vis\u00e9e somatique","author":"Vusler","year":"2018"},{"key":"10.1016\/j.therap.2023.09.007_bib0325","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1176\/appi.ajp.2016.16030336","article-title":"Hypnotic medications and suicide: risk, mechanisms, mitigation, and the FDA","volume":"174","author":"McCall","year":"2017","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.therap.2023.09.007_bib0330","doi-asserted-by":"crossref","first-page":"16r02037","DOI":"10.4088\/PCC.16r02037","article-title":"Prescribed benzodiazepines and suicide risk: a review of the literature","volume":"19","author":"Dodds","year":"2017","journal-title":"Prim Care Companion CNS Disord"},{"key":"10.1016\/j.therap.2023.09.007_bib0335","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/acps.13582","article-title":"Risk of suicide attempt and suicide associated with benzodiazepine: a nationwide case crossover study","volume":"148","author":"Tournier","year":"2023","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.therap.2023.09.007_bib0340","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1159\/000502295","article-title":"Newer-generation antidepressants and suicide risk","volume":"88","author":"Hayes","year":"2019","journal-title":"Psychother Psychosom"},{"key":"10.1016\/j.therap.2023.09.007_bib0345","doi-asserted-by":"crossref","DOI":"10.1136\/jech-2020-214611","article-title":"Suicide risk with selective serotonin reuptake inhibitors and other new-generation antidepressants in adults: a systematic review and meta-analysis of observational studies","author":"Hengartner","year":"2021","journal-title":"J Epidemiol Community Health"},{"key":"10.1016\/j.therap.2023.09.007_bib0350","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3233\/JRS-210034","article-title":"Restoring the two pivotal fluoxetine trials in children and adolescents with depression","volume":"33","author":"G\u00f8tzsche","year":"2022","journal-title":"Int J Risk Saf Med"},{"key":"10.1016\/j.therap.2023.09.007_bib0355","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1001\/archpsyc.63.3.332","article-title":"Suicidality in pediatric patients treated with antidepressant drugs","volume":"63","author":"Hammad","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.therap.2023.09.007_bib0360","doi-asserted-by":"crossref","first-page":"h4320","DOI":"10.1136\/bmj.h4320","article-title":"Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence","volume":"351","author":"Le Noury","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2023.09.007_bib0365","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/00004583-200107000-00010","article-title":"Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial","volume":"40","author":"Keller","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.therap.2023.09.007_bib0370","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/13811110701249889","article-title":"Continued antidepressant treatment and suicide in patients with depressive disorder","volume":"11","author":"S\u00f8nderg\u00e5rd","year":"2007","journal-title":"Arch Suicide Res"},{"key":"10.1016\/j.therap.2023.09.007_bib0375","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S2215-0366(19)30292-5","article-title":"US Food and Drug Administration approval of esketamine and brexanolone","volume":"6","author":"Cristea","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.therap.2023.09.007_bib0380","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S2215-0366(19)30394-3","article-title":"Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval","volume":"6","author":"Turner","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.therap.2023.09.007_bib0385","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1017\/S204579602000027X","article-title":"Esketamine clinical trials: reply to Maju et al","volume":"29","author":"Gastaldon","year":"2020","journal-title":"Epidemiol Psychiatr Sci"},{"key":"10.1016\/j.therap.2023.09.007_bib0390","doi-asserted-by":"crossref","first-page":"l5572","DOI":"10.1136\/bmj.l5572","article-title":"Esketamine for treatment resistant depression","volume":"366","author":"Jauhar","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2023.09.007_bib0395","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S2215-0366(19)30521-8","article-title":"Esketamine as a treatment for paediatric depression: questions of safety and efficacy","volume":"7","author":"Zimmermann","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.therap.2023.09.007_bib0400","first-page":"725","article-title":"Esk\u00e9tamine (Spravato\u00b0) et d\u00e9pression dite r\u00e9sistante","volume":"40","author":"Prescrire","year":"2020","journal-title":"Rev Prescrire"},{"key":"10.1016\/j.therap.2023.09.007_bib0405","unstructured":"Haute autorit\u00e9 de sant\u00e9. Commission de la transparence avis esk\u00e9tamine SPRAVATO. 2021. https:\/\/www.has-sante.fr [Accessed 31 August 2023 (34 pp.)]"},{"key":"10.1016\/j.therap.2023.09.007_bib0410","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1017\/S204579602100072X","article-title":"How to deprescribe esketamine in resistant depression? A point of view after first clinical uses","volume":"31","author":"Taillefer de Laportali\u00e8re","year":"2022","journal-title":"Epidemiol Psychiatr Sci"},{"key":"10.1016\/j.therap.2023.09.007_bib0415","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000510703","article-title":"Post-marketing safety concerns with esketamine: a disproportionality analysis of spontaneous reports submitted to the FDA adverse event reporting system","volume":"90","author":"Gastaldon","year":"2021","journal-title":"Psychother Psychosom"},{"key":"10.1016\/j.therap.2023.09.007_bib0420","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1017\/S0033291723001058","article-title":"Reporting of harms in clinical trials of esketamine in depression: a systematic review","volume":"53","author":"Taillefer de Laportali\u00e8re","year":"2023","journal-title":"Psychol Med"},{"key":"10.1016\/j.therap.2023.09.007_bib0430","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1177\/1039856217734677","article-title":"Suvorexant: scientifically interesting, utility uncertain","volume":"25","author":"Keks","year":"2017","journal-title":"Australas Psychiatry"},{"key":"10.1016\/j.therap.2023.09.007_bib0435","article-title":"Adverse reaction with suvorexant for insomnia: acute worsening of depression with emergence of suicidal thoughts","volume":"2017","author":"Petrous","year":"2017","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.therap.2023.09.007_bib0440","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.revmed.2012.12.011","article-title":"Troubles psychiatriques induits par la corticoth\u00e9rapie orale\u00a0: mise au point sur la nature, l\u2019incidence, les facteurs de risque et le traitement","volume":"34","author":"Ricoux","year":"2013","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.therap.2023.09.007_bib0445","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.4065\/81.10.1361","article-title":"Psychiatric adverse effects of corticosteroids","volume":"81","author":"Warrington","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.therap.2023.09.007_bib0450","doi-asserted-by":"crossref","first-page":"2172564","DOI":"10.1155\/2022\/2172564","article-title":"DNA methylation profiles of the DRD2 and NR3C1 genes in patients with recent-onset psychosis","volume":"2022","author":"Piao","year":"2022","journal-title":"Dis Markers"},{"key":"10.1016\/j.therap.2023.09.007_bib0455","doi-asserted-by":"crossref","first-page":"764279","DOI":"10.3389\/fphar.2021.764279","article-title":"Neuropsychiatric adverse events of montelukast: an analysis of real-world datasets and drug-gene interaction network","volume":"12","author":"Umetsu","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.therap.2023.09.007_bib0460","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jcf.2022.01.012","article-title":"Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis","volume":"21","author":"Martin","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.therap.2023.09.007_bib0465","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jcf.2017.05.008","article-title":"Worsening anxiety and depression after initiation of lumacaftor\/ivacaftor combination therapy in adolescent females with cystic fibrosis","volume":"16","author":"McKinzie","year":"2017","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.therap.2023.09.007_bib0470","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.psym.2017.04.001","article-title":"Cystic fibrosis transmembrane regulator modulators: implications for the management of depression and anxiety in cystic fibrosis","volume":"58","author":"Talwalkar","year":"2017","journal-title":"Psychosomatics"},{"key":"10.1016\/j.therap.2023.09.007_bib0475","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1016\/S1569-1993(21)01695-7","article-title":"270: Mental health and neurocognitive side effects after initiating elexacaftor\/tezacaftor\/ivacaftor","volume":"20","author":"Bathgate","year":"2021","journal-title":"J Cyst Fibro"},{"key":"10.1016\/j.therap.2023.09.007_bib0480","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/ppul.26412","article-title":"Management of neuropsychiatric symptoms in adults treated with elexacaftor\/tezacaftor\/ivacaftor","volume":"58","author":"Baroud","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.therap.2023.09.007_bib0485","doi-asserted-by":"crossref","first-page":"11","DOI":"10.24869\/psyd.2022.11","article-title":"Medication-induced psychotic disorder. A review of selected drugs side effects","volume":"34","author":"Niebrzydowska","year":"2022","journal-title":"Psychiatr Danub"},{"key":"10.1016\/j.therap.2023.09.007_bib0490","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000477313","article-title":"Antipsychotic-induced dopamine supersensitivity psychosis: pharmacology, criteria, and therapy","volume":"86","author":"Chouinard","year":"2017","journal-title":"Psychother Psychosom"},{"key":"10.1016\/j.therap.2023.09.007_bib0495","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/YCO.0000000000000598","article-title":"Dopamine D2 up-regulation in psychosis patients after antipsychotic drug treatment","volume":"33","author":"Thompson","year":"2020","journal-title":"Curr Opin Psychiatry"},{"key":"10.1016\/j.therap.2023.09.007_bib0500","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00213-013-3154-1","article-title":"A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder","volume":"228","author":"Takeuchi","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.therap.2023.09.007_bib0505","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/jamapsychiatry.2018.4149","article-title":"Association of aripiprazole with the risk for psychiatric hospitalization, self-harm, or suicide","volume":"76","author":"Montastruc","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.therap.2023.09.007_bib0510","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.therap.2020.12.010","article-title":"Towards personalized pharmacology: antipsychotics and schizophrenia","volume":"76","author":"Carton","year":"2021","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2023.09.007_bib0515","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1056\/NEJMoa1813751","article-title":"Psychosis with methylphenidate or amphetamine in patients with ADHD","volume":"380","author":"Moran","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2023.09.007_bib0520","first-page":"e34299","article-title":"Psychosis induced by methylphenidate in children and young patients with attention-deficit hyperactivity disorder","volume":"15","author":"Pasha","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.therap.2023.09.007_bib0525","doi-asserted-by":"crossref","first-page":"e956","DOI":"10.1038\/tp.2016.216","article-title":"Methylphenidate and the risk of psychotic disorders and hallucinations in children and adolescents in a large health system","volume":"6","author":"Man","year":"2016","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.therap.2023.09.007_bib0530","first-page":"126","article-title":"Quinolone-induced psychosis: an updated review","volume":"48","author":"Palma-Alvarez","year":"2020","journal-title":"Actas Esp Psiquiatr"},{"issue":"Suppl. 3","key":"10.1016\/j.therap.2023.09.007_bib0535","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000057838","article-title":"History of quinolones and their side effects","volume":"47","author":"Rubinstein","year":"2001","journal-title":"Chemotherapy"},{"key":"10.1016\/j.therap.2023.09.007_bib0540","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1128\/AAC.42.7.1831","article-title":"Determination of the excitatory potencies of fluoroquinolones in the central nervous system by an in vitro model","volume":"42","author":"Schmuck","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.therap.2023.09.007_bib0545","unstructured":"European Medical Agency (EMA). Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics. 2018. https:\/\/www.ema.europa.eu [Accessed 31 August 2023]"},{"key":"10.1016\/j.therap.2023.09.007_bib0550","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jad.2021.10.041","article-title":"Comparative effects of 15 antidepressants on the risk of withdrawal syndrome: a real-world study using the WHO pharmacovigilance database","volume":"297","author":"Quilichini","year":"2022","journal-title":"J Affect Disord"},{"key":"10.1016\/j.therap.2023.09.007_bib0555","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jpsychires.2017.02.008","article-title":"Drug-induced panic attacks: analysis of cases registered in the French pharmacovigilance database","volume":"90","author":"Abadie","year":"2017","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.therap.2023.09.007_bib0560","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/hup.465","article-title":"Drug induced nightmares\u00a0\u2013\u00a0an etiology based review","volume":"18","author":"Pagel","year":"2003","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.therap.2023.09.007_bib0565","unstructured":"Base de donn\u00e9es publique des m\u00e9dicaments. R\u00e9sum\u00e9 des caract\u00e9ristiques du produit : propranolol. https:\/\/base-donnees-publique.medicaments.gouv.fr [Accessed 31 August 2023]"},{"key":"10.1016\/j.therap.2023.09.007_bib0570","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1177\/02698811211034810","article-title":"\u03b2-adrenoceptor antagonists and nightmares: a pharmacoepidemiological-pharmacodynamic study","volume":"35","author":"Garcia","year":"2021","journal-title":"J Psychopharmacol"},{"issue":"Pt 5","key":"10.1016\/j.therap.2023.09.007_bib0575","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/eye.2000.225","article-title":"Nightmares with topical beta-blocker","volume":"14","author":"Negi","year":"2000","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.therap.2023.09.007_bib0580","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/hup.465","article-title":"Drug induced nightmares\u00a0\u2013\u00a0an etiology based review","volume":"18","author":"Pagel","year":"2003","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.therap.2023.09.007_bib0585","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1345\/aph.18150","article-title":"Drug-induced nightmares","volume":"33","author":"Thompson","year":"1999","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.therap.2023.09.007_bib0590","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.therap.2019.01.007","article-title":"Interest of pharmacoepidemiology for the study of psychotropic drugs","volume":"74","author":"Tournier","year":"2019","journal-title":"Therapie"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595723001701?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595723001701?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T19:58:26Z","timestamp":1711655906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595723001701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0040595723001701"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2023.09.007","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-induced psychiatric disorders: A pharmacovigilance update","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2023.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}